Dynavax Technologies (DVAX) Analysts See $-0.52 EPS; 5 Analysts Bullish Monroe Capital (MRCC)

October 13, 2017 - By Kurt Siggers

Among 6 analysts covering Monroe Capital (NASDAQ:MRCC), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Monroe Capital had 7 analyst reports since April 27, 2016 according to SRatingsIntel. The firm has “Neutral” rating by Robert W. Baird given on Monday, January 9. The stock of Monroe Capital Corp (NASDAQ:MRCC) has “Buy” rating given on Thursday, July 21 by Wunderlich. The firm earned “Buy” rating on Wednesday, April 27 by Janney Capital. Oppenheimer maintained it with “Buy” rating and $1700 target in Wednesday, August 9 report. The company was upgraded on Thursday, August 10 by Ladenburg Thalmann. The rating was downgraded by Ladenburg Thalmann on Wednesday, August 10 to “Neutral”. The stock has “Outperform” rating by Raymond James on Tuesday, August 16. See Monroe Capital Corp (NASDAQ:MRCC) latest ratings:

10/08/2017 Broker: Ladenburg Thalmann Old Rating: Neutral New Rating: Buy Upgrade
09/08/2017 Broker: Oppenheimer Rating: Buy New Target: $17.0000 Maintain

Analysts expect Dynavax Technologies Corporation (NASDAQ:DVAX) to report $-0.52 EPS on November, 6.They anticipate $0.38 EPS change or 42.22% from last quarter’s $-0.9 EPS. After having $-0.41 EPS previously, Dynavax Technologies Corporation’s analysts see 26.83% EPS growth. About 987,804 shares traded. Dynavax Technologies Corporation (NASDAQ:DVAX) has declined 63.84% since October 13, 2016 and is downtrending. It has underperformed by 80.54% the S&P500.

Since May 11, 2017, it had 1 buying transaction, and 0 sales for $88,447 activity. 5,710 shares were bought by KOENIG THEODORE L, worth $88,447.

About 62,528 shares traded. Monroe Capital Corp (NASDAQ:MRCC) has risen 14.25% since October 13, 2016 and is uptrending. It has underperformed by 2.45% the S&P500.

Investors sentiment increased to 2.73 in 2017 Q2. Its up 0.85, from 1.88 in 2017Q1. It improved, as 3 investors sold Monroe Capital Corp shares while 8 reduced holdings. 11 funds opened positions while 19 raised stakes. 5.06 million shares or 9.98% more from 4.60 million shares in 2017Q1 were reported. Wilbanks Smith & Thomas Asset Mngmt Limited reported 0.02% in Monroe Capital Corp (NASDAQ:MRCC). Advisors Asset Inc, Colorado-based fund reported 481,692 shares. Stephens Ar holds 0.04% or 71,589 shares. Janney Montgomery Scott Ltd Liability Corp has invested 0.04% of its portfolio in Monroe Capital Corp (NASDAQ:MRCC). Asset Management Inc reported 37,200 shares. Pnc Fincl Gru Inc invested in 2,000 shares or 0% of the stock. Freestone Capital Hldgs Ltd Liability Corp accumulated 0.02% or 13,923 shares. Ativo Cap Management Ltd Liability Corporation accumulated 66,013 shares or 0.27% of the stock. Advisory Rech Incorporated owns 381,021 shares. Jpmorgan Chase & reported 0% in Monroe Capital Corp (NASDAQ:MRCC). Bard Assoc Inc holds 119,237 shares. 2,341 are owned by Seabridge Investment Lc. Blair William & Il has invested 0.09% of its portfolio in Monroe Capital Corp (NASDAQ:MRCC). Silver Cap Management Lc holds 37,324 shares. 113,199 were reported by Blackrock Inc.

Monroe Capital Corporation is a closed-end, non-diversified management investment company. The company has market cap of $287.00 million. The Firm is a specialty finance firm focused on providing financing primarily to lower middle-market companies in the United States and Canada. It has a 15.76 P/E ratio. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation primarily through investments in senior, unitranche and junior secured debt, and unsecured subordinated debt and equity.

Investors sentiment increased to 2.33 in Q2 2017. Its up 1.18, from 1.15 in 2017Q1. It improved, as 8 investors sold Dynavax Technologies Corporation shares while 19 reduced holdings. 20 funds opened positions while 43 raised stakes. 34.68 million shares or 16.64% more from 29.73 million shares in 2017Q1 were reported. Blackrock has 3.13 million shares. Invesco Ltd invested in 52,239 shares. Manufacturers Life Ins The holds 41,320 shares. Weiss Multi owns 100,000 shares. Mariner Wealth Advsrs Limited Liability reported 28,324 shares. Ameritas Investment Prtnrs accumulated 4,309 shares. Kornitzer Cap Management Ks invested in 1.14M shares. Baker Bros Advsrs Ltd Partnership reported 75,000 shares or 0.01% of all its holdings. Blair William And Co Il has 0.13% invested in Dynavax Technologies Corporation (NASDAQ:DVAX) for 1.84M shares. Rhumbline Advisers holds 60,503 shares. Ameriprise Fincl holds 0% or 887,272 shares. Parametric Portfolio Assocs Ltd Co invested in 30,755 shares or 0% of the stock. Credit Suisse Ag holds 46,922 shares. Goldman Sachs Group Inc reported 0% stake. D E Shaw And stated it has 739,944 shares or 0.01% of all its holdings.

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The company has market cap of $1.33 billion. The Firm is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor stimulation. It currently has negative earnings. The Company’s product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com